The ability to predict which prostate cancer patients will benefit most from hormone-blocking therapy could fundamentally change treatment planning for men with advanced disease. A new validation study demonstrates that a predictive tool called the NADIR model accurately identifies patients likely to achieve deep PSA suppression in real clinical practice, potentially guiding more personalized treatment approaches.
The Hiroshima University study examined 186 men with metastatic castration-sensitive prostate cancer receiving androgen receptor signaling inhibitor therapy. Using the NADIR scoring system, researchers successfully predicted which patients would achieve PSA levels below 0.2 ng/mL within six months—a key marker of treatment effectiveness. The model showed strong discrimination, with favorable PSA responses occurring in 61.3% of high-scoring patients compared to just 17.7% in the lowest-scoring group.
This validation represents a significant step toward precision medicine in prostate cancer treatment. The NADIR model, originally developed from clinical trial data, has now proven its worth in everyday clinical settings where patients often have more complex medical histories and varying treatment adherence. The ability to stratify patients based on their likelihood of achieving deep PSA suppression could help oncologists make more informed decisions about treatment intensity and monitoring schedules. However, the study's retrospective design and single-institution origin limit broader applicability. Future multicenter prospective studies will be essential to establish whether NADIR-guided treatment decisions actually improve long-term outcomes like survival and time to disease progression.